Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling |
Xiao, Yongtao
(Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University)
Zhou, Kejun (Shanghai Institute of Pediatric Research) Lu, Ying (Shanghai Institute of Pediatric Research) Yan, Weihui (Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University) Cai, Wei (Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University) Wang, Ying (Department of Pediatric Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University) |
1 | Hudgins, J. D., Goldberg, V., Fell, G. L., Puder, M. & Eisenberg, M. A. Reducing time to antibiotics in children with intestinal failure, central venous line, and fever. Pediatrics 140, e20171201 (2017). DOI |
2 | Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174-180 (2011). DOI |
3 | Musso, G., Gambino, R. & Cassader, M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu. Rev. Med. 62, 361-380 (2011). DOI |
4 | Marchesi, J. R. et al. The gutmicrobiota and host health: a new clinical frontier. Gut 65, 330-339 (2016). DOI |
5 | Canfora, E. E., Jocken, J. W. & Blaak, E. E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11, 577-591 (2015). DOI |
6 | Cox, L. M. & Blaser, M. J. Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 11, 182-190 (2015). DOI |
7 | Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108, (Suppl 1), 4554-4561 (2011). DOI |
8 | Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008). DOI |
9 | Vrieze, A. et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 60, 824-831 (2014). DOI |
10 | Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225-235 (2013). DOI |
11 | Lacaille, F. et al. Intestinal failure-associated liver disease: a position paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation. J. Pediatr. Gastroenterol. Nutr. 60, 272-283 (2015). DOI |
12 | Wessel, J., Kotagal, M. & Helmrath, M. A. Management of Pediatric Intestinal Failure. Adv. Pediatr. 64, 253-267 (2017). DOI |
13 | Xiao, Y. T., Cao, Y., Zhou, K. J., Lu, L. N. & Cai, W. Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure. Sci. Rep. 6, 39264 (2016). DOI |
14 | Ridlon, J. M., Kang, D. J. & Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241-259 (2006). DOI |
15 | Russell, D. W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137-174 (2003). DOI |
16 | Jia, W., Xie, G. & Jia, W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15, 111-128 (2018). DOI |
17 | Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744 (2000). DOI |
18 | Chiang, J. Y. Bile acids: regulation of synthesis. J. Lipid Res. 50, 1955-1966 (2009). DOI |
19 | De Fabiani, E. et al. The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J. Biol. Chem. 276, 30708-30716 (2001). DOI |
20 | Green, R. M., Beier, D. & Gollan, J. L. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111, 193-198 (1996). DOI |
21 | Kosters, A. & Karpen, S. J. The role of inflammation in cholestasis: clinical and basic aspects. Semin. Liver Dis. 30, 186-194 (2010). DOI |
22 | Botham, K. M. & Boyd, G. S. The metabolism of chenodeoxycholic acid to betamuricholic acid in rat liver. Eur. J. Biochem. 134, 191-196 (1983). DOI |
23 | Gadaleta, R. M., Cariello, M., Sabba, C. & Moschetta, A. Tissue-specific actions of FXR in metabolism and cancer. Biochim. Biophys. Acta 1851, 30-39 (2015). DOI |
24 | Pereira-Fantini, P. M. et al. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. J. Hepatol. 61, 1115-1125 (2014). DOI |
25 | Mutanen, A., Lohi, J., Heikkila, P., Jalanko, H. & Pakarinen, M. P. Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure. J. Hepatol. 62, 1391-1397 (2015). DOI |
26 | Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J. & Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678-693 (2008). DOI |
27 | Meier, P. J. & Stieger, B. Bile salt transporters. Annu. Rev. Physiol. 64, 635-661 (2002). DOI |
28 | Uppal, H. et al. Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41, 168-176 (2005). DOI |
29 | Zollner, G., Marschall, H. U., Wagner,M. & Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251 (2006). DOI |
30 | Trauner, M. & Boyer, J. L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83, 633-671 (2003). DOI |
31 | Gura, K. M. et al. Pediatric Intestinal Failure-Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. J. Parenter. Enter. Nutr. 42, 455-462 (2018). |
32 | Stueck, A. E. Intestinal failure-associated liver disease: risks and regression. Liver. Int. 38, 35-37 (2018). DOI |
33 | Wang, P. et al. Alterations in intestinal microbiota relate to intestinal failureassociated liver disease and central line infections. J. Pediatr. Surg. 52, 1318-1326 (2017). DOI |
34 | Kim, I. et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664-2672 (2007). DOI |
35 | Al-Shahwani, N. H. & Sigalet, D. L. Pathophysiology, prevention, treatment, and outcomes of intestinal failure-associated liver disease. Pediatr. Surg. Int. 33, 405-411 (2017). DOI |
36 | Ridlon, J. M., Kang, D. J., Hylemon, P. B. & Bajaj, J. S. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332-338 (2014). DOI |
37 | Kisiela, M., Skarka, A., Ebert, B. & Maser, E. Hydroxysteroid dehydrogenases (HSDs) in bacteria: a bioinformatic perspective. J. Steroid Biochem. Mol. Biol. 129, 31-46 (2012). DOI |
38 | Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368 (1999). DOI |
![]() |